New Technology in Treatment of Bladder Cancer

The results were presented at the 2000 meeting of the Brussels (Belgium) Congress of the European Association of Urologists and at a scientific conference of the Israel Cancer Society.

The patients in the studies were divided into two groups. In one (randomized) study, patients received either the new treatment or traditional Mitomycin instillations as prophylactic. This group included patients with repeated trans-urethral resections of transitional cell bladder tumors. The patients having the new treatment showed a much lower recurrence rate (20%) than patients receiving conventional treatment (70%).

The second group included patients with multifocal transitional cell carcinoma who had experienced several surgical interventions for removing tumorous tissue. In this group, 71% of patients had a complete regression of tumors. A partial response (50% regression) was achieved in 18%, while 11% experienced no response.

The hyperthermia treatment, performed on an outpatient basis, consists of eight weekly sessions of controlled hyperthermia followed by four monthly sessions. Each session lasts one hour. This innovative technology is offered by Medical Enterprises. It has been successful on hundreds of subjects in Israel, Italy and Germany.


Related Links:
Medical Enterprises